332 related articles for article (PubMed ID: 33727259)
1. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Adib E; Klonowska K; Giannikou K; Do KT; Pruitt-Thompson S; Bhushan K; Milstein MI; Hedglin J; Kargus KE; Sholl LM; Tsuji J; Hyman DM; Sisk A; Shapiro GI; Vargas HA; Harding JJ; Voss MH; Iyer G; Kwiatkowski DJ
Clin Cancer Res; 2021 Jul; 27(14):3845-3853. PubMed ID: 33727259
[TBL] [Abstract][Full Text] [Related]
2. PTEN Expression, Not Mutation Status in
Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of everolimus in patients with advanced solid malignancies with
Devarakonda S; Pellini B; Verghese L; Park H; Morgensztern D; Govindan R; Suresh R; Oppelt P; Baggstrom MQ; Wu N; Waqar SN
J Thorac Dis; 2021 Jul; 13(7):4054-4062. PubMed ID: 34422335
[TBL] [Abstract][Full Text] [Related]
5. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
[TBL] [Abstract][Full Text] [Related]
7. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
Kim ST; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
BMC Cancer; 2017 Mar; 17(1):211. PubMed ID: 28330462
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of everolimus in metastatic urothelial cancer.
Milowsky MI; Iyer G; Regazzi AM; Al-Ahmadie H; Gerst SR; Ostrovnaya I; Gellert LL; Kaplan R; Garcia-Grossman IR; Pendse D; Balar AV; Flaherty AM; Trout A; Solit DB; Bajorin DF
BJU Int; 2013 Aug; 112(4):462-70. PubMed ID: 23551593
[TBL] [Abstract][Full Text] [Related]
11. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
12. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
13. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
[TBL] [Abstract][Full Text] [Related]
14. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE
Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
[TBL] [Abstract][Full Text] [Related]
16. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
17. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
18. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
[TBL] [Abstract][Full Text] [Related]
19. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
[TBL] [Abstract][Full Text] [Related]
20. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
